Premium
Evaluation of butaperazine in chronic schizophrenia
Author(s) -
Clark Mervin L.,
Ray Thomas S.,
Huber Wolfgang K.,
Willis David,
Ramsey H. Rudy
Publication year - 1968
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196896757
Subject(s) - chlorpromazine , placebo , extrapyramidal symptoms , orthostatic vital signs , antipsychotic , schizophrenia (object oriented programming) , psychiatry , medicine , clinical trial , psychology , anesthesia , alternative medicine , pathology , blood pressure
A clinical trial was conducted to evaluate butaperazine, a piperazine phenothiazine, against chlorpromazine and placebo for 16 weeks in 67 chronic schizophrenic women. Responses were made based on psychiatric and psychological interviews, general ward behavior, and psychological tests. Significant improvement of the chlorpromazine patients attested to the sensitivity of the method. Butaperazine was found to be an effective antipsychotic agent of the order of chlorpromazine. Butaperazine caused more frequent extrapyramidal and fewer orthostatic symptoms.